Transient auditory nerve demyelination as a new mechanism for hidden hearing loss

Guoqiang Wan1,2 & Gabriel Corfas1

Hidden hearing loss (HHL) is a recently described auditory neuropathy believed to contribute to speech discrimination and intelligibility deficits in people with normal audiological tests. Animals and humans with HHL have normal auditory thresholds but defective cochlear neurotransmission, that is, reduced suprathreshold amplitude of the sound-evoked auditory nerve compound action potential. Currently, the only cellular mechanism known for HHL is loss of inner hair cell synapses (synaptopathy). Here we report that transient loss of cochlear Schwann cells results in permanent auditory deficits characteristic of HHL. This auditory neuropathy is not associated with synaptic loss, but rather with disruption of the first heminodes at the auditory nerve peripheral terminal. Thus, this study identifies a new mechanism for HHL, highlights the long-term consequences of transient Schwann cell loss on hearing and might provide insights into the causes of the auditory deficits reported in patients that recover from acute demyelinating diseases such as Guillain–Barré syndrome.
n the mammalian cochlea, acoustic stimuli are detected by inner hair cells (IHCs), which transduce and transform them into synaptic signals to the primary auditory sensory neurons, the spiral ganglion neurons (SGNs). These neurons then relay the acoustic information to the central auditory circuits. Thus, proper function of both sensory cells and neurons is essential for normal hearing and auditory communication, and degeneration of either component causes sensorineural hearing loss. This type of hearing loss, which affects 320 million people worldwide, is characterized by permanent elevation of auditory thresholds, that is, the minimal sound pressure levels (SPLs) that evoke an auditory or neural response at specific sound frequencies. Until recently, it was believed that auditory processing is normal in subjects with normal thresholds, even after recovery from a temporary threshold shift (TTS) due to noise exposure, and that hearing deficits in those cases were due to central problems. However, recent animal and human studies indicate that moderate noise exposures or ageing can result in a new form of peripheral hearing loss called 'hidden hearing loss (HHL)'.

HHL can be detected physiologically and is characterized by normal auditory thresholds but reduced suprathreshold amplitude of the sound-evoked SGN compound action potential (AP) (the first peak of the auditory brainstem response (ABR) waveform), and by the alteration in the ratio between the peak of the ABR waveform generated by hair cells (summatting potential (SP)) and the peak I of the ABR waveform (AP). The reduced neuronal activation seen in HHL has been proposed to result in degradation of the temporal coding of suprathreshold sounds and deficits in speech discrimination and intelligibility, particularly in a noisy environment; however, the latter are not diagnostic of HHL, as they could be also caused by central processing deficits. HHL has been proposed to lead to hyperactivation of central auditory synapses, thus possibly contributing to tinnitus. Until now, loss or dysfunction of IHC synapses has been the only proposed mechanism of HHL. Here we report an additional cellular mechanism for HHL.

In the cochlea, sensory hair cells and neurons are in close association with several types of glial and glia-like cells. Hair cells are surrounded by supporting cells, SGN axons are myelinated by Schwann cells and spiral ganglion cell bodies are wrapped by satellite cells. As part of our ongoing efforts to define the roles of different populations of cochlear glia play in hearing and deafness, we investigated the consequences of Schwann cell ablation in the mature cochlea. We found that acute Schwann cell loss causes rapid auditory nerve demyelination, which is followed by robust Schwann cell regeneration and axonal remyelination. Surprisingly, this transient Schwann cell loss results in a permanent auditory impairment characteristic of HHL. However, this HHL differs from that seen after noise exposure or ageing in that it occurs without alterations in synaptic density but rather correlates with a specific and permanent disruptions of the first heminodes at the auditory nerve axon close to the IHCs. Furthermore, the two types of HHL occur independently (noise exposures that cause HHL do not disrupt heminodes) and they are additive. Together, these results uncover a new mechanism for the pathogenesis of HHL and a new consequence of myelin defects on the normal function of the nervous system.

Figure 1 | Plp1 is expressed only by Schwann and satellite cells in the mature cochlea. (a) Schematic illustration of the IHC, SGNs and their associated glial/glial-like cells. (b–e) Images of the organ of Corti of Plp1/eGFP mice at different postnatal ages (P3–P35) show that the Plp1 promoter is active in supporting cells associated with IHCs until P15, but by P21 it is silent. Three rows of outer hair cells (OHCs) and one row of IHCs were labelled by Myo7a. (f–i) Images of cochlear whole mounts of Plp1/eGFP mice show that the Plp1 promoter is active in auditory nerve Schwann cells in the OSL at all ages examined. (j–m) Images of sections through the spiral ganglion of Plp1/eGFP mice show that the Plp1 promoter is active in satellite cells surrounding SGNs at all ages examined. Sections were co-labelled with a marker for glial cells (Sox2) and nuclei (4,6-diamidino-2-phenylindole, DAPI). Asterisks and arrow heads indicate SGN cell bodies and associated satellite cells, respectively.
Results

Ablation and regeneration of Schwann cells in mature cochlea.

To test the consequence of Schwann and satellite cell ablation on the cochlea, we used conditional expression of diphtheria toxin fragment A (DTA) in proteolipid protein 1 (Plp1)-expressing cells at P21. This strategy was based on the pattern of Plp1 promoter activity in the postnatal cochlea. As shown in Fig. 1, in the neonatal mouse cochlea (P1–P15) Plp1 is expressed by Schwann cells, satellite cells, as well as inner phalangeal and inner border cells (IPhC/IBCs), the supporting cells surrounding IHCs18. However, by P21 Plp1 promoter activity in IPhC/IBCs is undetectable (Fig. 1a–e), while is maintained in Schwann cells along the auditory nerve fibres (ANFs) located at the osseous spiral lamina (OSL) (Fig. 1a,f–i) and satellite cells surrounding the cell bodies of SGNs in Rosenthal’s canal (Fig. 1a,j–m).

As anticipated from prior studies of mice with DTA-induced ablation of Plp1-expressing cells19, tamoxifen intraperitoneal (i.p.) injection to mice carrying Plp1/CreERT2 transgene and Rosa26DTA alleles [DTA(+/–):Plp1/Cre(+/–)] from P21 to 23 resulted in uncoordinated gait and hind-limb paralysis between 1 and 2 weeks post DTA expression followed by complete recovery of normal gait by 3–4 weeks post DTA expression. This is consistent with the robust regenerative capacity of Plp1-expressing glia cells19. Interestingly, although DTA induction at P35 results in significant mortality 3 weeks later (ref. 19 and our unpublished data), we found that ablation of Plp1-expressing cells at P21 does not result in lethality. These observations suggest that the health effects of loss of Plp1+ cells increase with age.

Based on the findings described in Fig. 1, we anticipated that tamoxifen treatment of DTA(+/–):PlpCre1(+/-) mice from P21 to P23 would ablate Schwann and satellite cells without affecting the supporting cells in the organ of Corti. Indeed, immunostaining of cochlear whole mounts with the Schwann cell marker Sox10 or myelin basic protein (MBP) showed that DTA transgene activation at P21 results in robust ablation of Schwann cells along the ANFs within 1 week after tamoxifen injection (Supplementary Fig. 1a–d). In contrast, IPhC/IBCs, which are labelled by Sox2 or GLAST, are spared from DTA-mediated ablation at this age (Supplementary Fig. 1e,f). With this model in hand, we analysed the effects of the Schwann cell loss on cochlear structure and function at different intervals, from 1 week to 1 year after induction of Schwann cell ablation.

Studies of other peripheral nerves have demonstrated that denervation and Schwann cell loss is usually followed by extensive proliferation of undifferentiated Schwann cells, which repopulate and remyelinate the nerves20,21. Accordingly, analysis of 5-ethyl-2′-deoxyuridine (EdU) incorporation showed that 1 week after DTA transgene activation, the auditory nerves of mice with Schwann cell ablation display a dramatic increase in the number of EdU+ cells (Fig. 2c,d) compared with controls (Fig. 2a,b). Furthermore, lineage tracing with an inducible

![Figure 2](image-url)

Figure 2 | Schwann cells in the auditory nerve regenerate within weeks after DTA induction in Plp1-expressing cells. (a–d) Tamoxifen induction of DTA expression at P21 promotes EdU incorporation in DTA(+/–):Plp1/Cre(+/-) cochlea (c,d), but not the control cochlea (a,b). Mice were injected with tamoxifen at P21–23, with EdU at P29 and tissues harvested at P30. (b,d) High-magnification views of the dashed boxes in a and e, respectively. HP, habenula perforata; oC, organ of Corti; OSL, osseous spiral lamina. (e–h) Lineage tracing of EdU+ cells shows that they are Schwann cells that escaped DTA-mediated death. (h) Merged image of EdU labelling (e, green), Plp1-driven tdTomato (f, red) and nuclei (g, blue). Arrow heads in h indicate surviving Plp1-expressing cells incorporated EdU. (i–l) tdTomato-positive cells repopulate in 4 weeks after tamoxifen induction. Control (i,k) and DTA(+/–):tdTomato(+/-):Plp1/Cre(+/-) mice (j,l) were injected with tamoxifen from P21 to 23 and cochlear tissues analysed either 1 week (j,l, Tmx+1 week) or 4 weeks (k,l, Tmx+4 weeks) later.
tdTomato reporter in DTA(+/−):tdTomato(+/−):Plp1/Cre(+/−) mice revealed that these EdU-positive cells are generated by Plp1-expressing cells that most probably escaped DTA-mediated ablation (Fig. 2e–h), that is, Schwann cells in which recombination occurred in the Rosa26tdTomato allele but not in the Rosa26DTA allele. Further analysis showed that the surviving tdTomato+ cells 1 week post induction (Fig. 2i,j) repopulate the OSL to levels similar to that of controls by 1 month post induction (Fig. 2k,l).

Similar robust regeneration was observed for satellite cells (Supplementary Fig. 2). Although satellite cells are clearly lost 1 month post induction (Fig. 2k,l), they repopulate the OSL to levels similar to that of controls by 1 month post induction in 3 individual animals in each group. *P < 0.05 and **P < 0.001 by two-way analysis of variance (ANOVA) followed by Bonferroni’s post-test. (c–g) ANFs of DTA(+−):Plp1/Cre(+−) cochlea have normal axon caliber and myelin thickness 16 weeks after tamoxifen induction. Axonal diameter (c,e) and g-ratio (d,f,g) are normal in DTA(+/−):Plp1/Cre(+−) cochlea 16 weeks after tamoxifen treatment. g-ratio was calculated as axon diameter / (axon + myelin sheath diameter). For e–g, n = 3 animals of each group with > 300 axons per group. Data are expressed as mean ± s.d.

Schwann cell regeneration and remyelination of SGN axons. In models of axon injury or demyelinating neuropathy, damaged Schwann cells regenerate and re-myelinate axons20,22,23. We therefore examined the consequence of DTA-induced Schwann cell ablation on ANF myelin. DTA expression resulted in acute demyelination of the ANFs within 1 week post induction (Fig. 3a,b), consistent with loss of Schwann cell markers at this time point (Supplementary Fig. 1). At 4 weeks post induction, when Schwann cells have repopulated (Fig. 2i,j), we observed significant yet incomplete remyelination (Fig. 3a,b). By 16 weeks post induction, myelinated axon density completely recovered in DTA(+/−):Plp1/Cre(+−) cochleas (Fig. 3a,b). Moreover, at 16 weeks post induction, axons from DTA(+−):Plp1/Cre(+−) cochleas had
normal axon diameters (Fig. 3c,e,g) and myelin thickness (Fig. 3d,f,g). These results indicate that acute Schwann cell ablation results in rapid cell regeneration followed by remarkable remyelination, leading to fibres with normal axon caliber and myelin thickness.

Transient Schwann cell ablation causes permanent HHL.

Conduction block is the fundamental finding in clinically important acquired demyelinating neuropathies such as acute inflammatory demyelinating polyneuropathy and chronic inflammatory demyelinating polyneuropathy\(^24\). Therefore, given the dramatic demyelination we observed in ANFs on activation of the DTA transgene, we anticipated that mice would display significant hearing abnormalities soon after induction, and that these defects would resolve within 4 months as the nerve remyelinated. However, thresholds for the ABR and distortion product otoacoustic emission (DPOAE), which reflect the function of IHCs and outer hair cells, respectively, were not affected by the lack of myelin in ANFs (Supplementary Fig. 3a,b), indicating that these mice were ‘audiologically normal.’ In contrast, the suprathreshold amplitudes of the ABR peak 1, which represent the summed activity of the SGNs, were significantly reduced (Fig. 4a and Supplementary Fig. 4).

Furthermore, the suprathreshold latencies and widths of the ABR peak 1, which reflect in part the conduction velocity of the auditory nerve, were both severely affected (Fig. 4b,c and Supplementary Fig. 5). Specifically, mice with DTA-induced Schwann cell ablation have increased P1 latencies (Fig. 4b and Supplementary Fig. 5) and P1 widths (Fig. 4c) at all cochlear frequencies examined (5.6–32 kHz). Surprisingly, the effects of Schwann cell ablation on P1 amplitudes, latencies and widths do not reverse even 16 weeks post induction, when Schwann cells and myelin have regenerated (Figs 2 and 3 and Supplementary Fig. 2). Further support to the conclusion that the transient demyelination results in HHL was provided by analysis of the SP/AP ratios (amplitudes of SP/amplitudes of AP) (Fig. 5a), which can be used as a differential diagnosis for HHL in both mice and humans\(^5,9\). Transient Schwann cell ablation did not affect SP at all time points (Fig. 5b), further demonstrating that Schwann cell loss did not alter hair cell function (Supplementary Figs 1 and 3). In contrast, peak 1 AP amplitudes in DTA(+/−)/Plp1/Cre(+/−) mice were reduced at all time points (Fig. 5c), suggestive of cochlear neural dysfunction. Furthermore, SP/AP ratios were significantly reduced 4–16 weeks after Schwann cell ablation (Fig. 5d). These findings indicate that transient Schwann cell ablation results in prolonged auditory neuropathy and HHL.

**Demyelination-induced HHL is not caused by synapse loss.**

Loss of synapses between IHCs and SGNs is currently the only

---

**Figure 4 | Transient Schwann cell ablation results in persistent impairment of auditory physiology.** Mice were injected with tamoxifen from P21 to 23 and ABR tests were performed 1, 4, 8 and 16 weeks later. At all time points examined, ABR P1 supra-threshold amplitudes (a) are reduced, ABR P1 latencies (b) are increased and ABR P1 widths (c) are increased in DTA(+/−)/Plp1/Cre(+/−) mice. ABR P1 amplitudes, latencies and widths were analysed at 70 dB SPL. Tmx+1 week, n = 17–21; Tmx+4 weeks, n = 16–20; Tmx+8 weeks, n = 10–14; Tmx+16 weeks, n = 7–8 of each animal group. ***P < 0.001 by two-way ANOVA. Data are expressed as mean ± s.e.m.
known histological correlate of HHL and synapse loss has been reported to occur in some demyelinating disorders, for example, in Charcot–Marie–Tooth (CMT) disease and multiple sclerosis. Therefore, we analysed the density of IHC ribbon synapses in control and demyelinated mice by immunostaining for the presynaptic ribbon and postsynaptic receptor patches using antibodies against CIBP2 and GluA2 (ref. 15). At 4 weeks post induction, when remyelination was complete but HHL was robust, IHC synapse density was the same in DTA(+/-):Plp1/Cre(+/–) mice 4, 8 and 16 weeks after tamoxifen induction. Tmx + 1 week, n = 17–21; Tmx + 4 weeks, n = 16–20; Tmx + 8 weeks, n = 10–14; Tmx + 16 weeks, n = 7–8 of each animal group. *P < 0.05, **P < 0.01 and ***P < 0.001 by two-way ANOVA. Data are expressed as mean ± s.e.m.

**HHL is associated with permanent heminodal disruption.** The observation that ABR P1 latency is longer after transient demyelination suggested that other aspects of myelin–axon interactions could be disrupted. Therefore, we examined whether the transient demyelination alters node of Ranvier density in auditory axons. Immunostaining for the paranodal protein Caspr in combination with the myelin protein Plp1 showed that in the control P30 cochlea, nodes of Ranvier can be clearly observed along the ANFs in OSL (Fig. 7a), whereas heminodes formed by the first Schwann cells close to the IHCs can be seen at the habenula perforata (HP), the perforations in the OSL through which auditory fibres pass on their way to and from the organ of Corti (Fig. 7a, see also Fig. 1a). Interestingly, the first 50 μm of the auditory nerve after the heminodes has a low density of nodes of Ranvier, indicating that consistent with previous reports, the myelin segments generated by the Schwann cells closest to the IHC are about that length. As expected for a severely demyelinated nerve, the appearance of nodes and heminodes was disrupted in DTA(+/-):Plp1/Cre(+/–) cochlea 1 week after DTA induction (Fig. 7b).

**Figure 5 | Auditory APs and SPs are differentially affected by transient Schwann cell ablation.** Mice were injected with tamoxifen from P21 to 23 and ABR tests were performed 1, 4, 8 and 16 weeks later. (a) Averaged ABR traces of control and DTA(+/-):Plp1/Cre(+/–) mice at 11.3 kHz, 70 dB SPL. Five ABR peaks are labelled with I-V. Arrows indicate SP and ABR P1 AP. (b) The SP of DTA(+/-):Plp1/Cre(+/–) mice are not affected at all time points examined. (c) ABR P1 AP were reduced in DTA(+/-):Plp1/Cre(+/–) mice at all time points examined. (d) Ratios of SP/AP are increased in DTA(+/-):Plp1/Cre(+/–) mice 4, 8 and 16 weeks after tamoxifen induction. Tmx + 1 week, n = 17–21; Tmx + 4 weeks, n = 16–20; Tmx + 8 weeks, n = 10–14; Tmx + 16 weeks, n = 7–8 of each animal group. *P < 0.05, **P < 0.01 and ***P < 0.001 by two-way ANOVA. Data are expressed as mean ± s.e.m.
Myelination of the peripheral nervous system (PNS) is important for normal conduction of APs and synchronized transmission of neural impulses, and damage to peripheral axons and their myelin sheaths causes many forms of peripheral neuropathy, such as CMT disease and Guillain–Barre´ syndrome (GBS). In this study, we uncover a new consequence of myelin pathology; that is, that transient Schwann cell loss results in permanent hearing loss (permanent threshold shifts) and central auditory demyelination, raising the possibility that exposure to noise that induce TTS and HHL could also affect auditory nerve nodal structures. Therefore, we generated HHL in wild-type mice by exposing them to an octave-band noise (8–16 kHz, 98 dB SPL for 2 h). Two weeks after noise exposure, both ABR and DPOAE thresholds had recovered (Supplementary Fig. 8a,b), whereas the suprathreshold ABR P1 amplitudes were reduced at higher frequencies (Supplementary Fig. 8c). Consistent with previous reports, ABR P1 latencies were not significantly affected by noise exposure (Supplementary Fig. 8d), whereas ribbon synapse loss was evident at 32 kHz but not 11.3 kHz, consistent with a high-frequency HHL due to synaptopathy (Supplementary Fig. 8e–i). In contrast, the heminodes at the HP appeared normal (Supplementary Fig. 8j–m), suggesting that exposure to synaptopathic noise does not alter nodal organization.

Noise exposure causes HHL without affecting heminodes. Exposure of rodents to noise levels higher than those that induce TTSs and HHL (110 versus 98 dB SPL) results in permanent hearing loss (permanent threshold shifts) and central auditory demyelination, raising the possibility that exposure to noise that induce TTS and HHL could also affect auditory nerve nodal structures. Therefore, we generated HHL in wild-type mice by exposing them to an octave-band noise (8–16 kHz, 98 dB SPL for 2 h). Two weeks after noise exposure, both ABR and DPOAE thresholds had recovered (Supplementary Fig. 8a,b), whereas the suprathreshold ABR P1 amplitudes were reduced at higher frequencies (Supplementary Fig. 8c). Consistent with previous reports, ABR P1 latencies were not significantly affected by noise exposure (Supplementary Fig. 8d), whereas ribbon synapse loss was evident at 32 kHz but not 11.3 kHz, consistent with a high-frequency HHL due to synaptopathy (Supplementary Fig. 8e–i). In contrast, the heminodes at the HP appeared normal (Supplementary Fig. 8j–m), suggesting that exposure to synaptopathic noise does not alter nodal organization.

We also discover that such disruption causes auditory neuropathy, and the other caused by transient Schwann cell loss and involving nodal disruption. To test whether these two forms of HHL interact, we subjected mice that had undergone demyelination (DTA(+/−):Plp1/Cre(+/−)) at 3 weeks of age and their control counterparts (DTA(+/−) mice) to noise exposure that causes synaptopathy at 8 weeks of age, and analyzed their auditory function 2 weeks later (Fig. 9a). As shown above, 4 weeks after DTA-mediated Schwann cell ablation mice displayed HHL involving alterations in ABR Peak 1 amplitude and latency (Fig. 9b–d), which persisted even after noise exposure (Fig. 9e–g). Remarkably, noise exposure induced further decrease in ABR Peak 1 amplitudes beyond the one produced by demyelination (Fig. 9h–i) and the magnitudes of the shift in amplitudes were the same as in mice that had no demyelination (Fig. 9j–p). Furthermore, ABR P1 latencies remained unaffected after noise exposure in both demyelinated and control mice, indicating that the noise produced the same type of pathology independent of the prior demyelination (Fig. 9i,m,p). These findings indicate that exposure to synaptopathic noise causes additional degradation of neural output from the cochlea even when mice already suffer from HHL caused by transient Schwann cell loss. Thus, HHL caused by transient Schwann cell ablation is mechanistically distinct from that resulting from cochlear synaptopathy.
Both cochlear type I afferents (SGNs) and medial olivocochlear efferents are myelinated; however, it is unlikely that the auditory deficits we found after transient Schwann cell ablation are caused by damage to cochlear efferent nerves. First, sound-evoked medial olivocochlear activity is greatly depressed by anaesthesia during physiological recordings, thus should contribute little to our measurements of ABR amplitudes. Most importantly, complete lesion of cochlear efferent nerves fails to impair ABR peak 1 latencies (Maison et al., personal communications), further arguing against possible contribution of efferent nerves towards the auditory deficits observed in this study.

The bipolar SGNs form point-to-point connections between the sensory hair cells and neurons in the cochlear nucleus. At the CNS peripheral processes, the unmyelinated afferent terminals are tightly coupled to the ribbon synapses, whereas the myelinated axons extend from the HP to the SGN somata (Fig. 1a). Once the central SGN process enters the central nervous system (CNS), it becomes myelinated by oligodendrocytes. We used a mouse model of demyelination that results in loss of both Schwann cells in the peripheral nervous system and oligodendrocytes. In addition, the first heminode at the HP formed by Schwann cells is believed to be the initial spike generator of the SGNs. Moreover, it has been shown that in this mouse model CNS neurons remyelinate robustly and recover function after DTA-mediated oligodendrocyte ablation, further excluding the involvement of central auditory components in this study. Thus, the physiological changes we observed after Schwann cell ablation are most likely due to alterations in the peripheral auditory components, that is, SGN synaptic terminal, axon or somata myelination or neuronal survival (refer to Fig. 1a).

Synaptic dysfunction is known to result in defects in SGN neural amplitudes and latencies. However, synaptic density was not affected by Schwann cell ablation and demyelination. Although we did not examine whether synapses were transiently disrupted, it is unlikely to be that transient synaptopathy, if it occurred, could contribute to the persistent pathophysiology, as we have shown that when synapses regenerate after acute loss the auditory deficits recover as well. As with the nerve terminals, the SGN cell bodies were also unaffected after transient loss of Schwann and satellite cells. Satellite cells express glutamine synthetase for converting ammonia and glutamate to glutamine, which is important for metabolizing excess glutamate and preventing excitotoxicity. Satellite cells are also important for neuronal survival as knockout of sapB from these cells resulted in progressive neuronal death. Complete regeneration of the spiral ganglion satellite cells in our study is consistent with the remarkable spontaneous proliferation and regeneration of satellite cells in other sensory ganglia. Temporal regeneration of the satellite cells and wrapping on SGN cell bodies may be important to preserve the survival and function of the SGNs.

In animal models of central and peripheral demyelinating diseases, many axons remyelinate but with significantly thinner myelin sheaths and shorter internodal lengths. Intriguingly,
after transient Schwann cell loss and massive axonal demyelination in response to DTA expression, we observed complete remyelination of ANFs at the OSL featuring normal myelin thickness and nodal density. It is worth noting that DTA induction results in damage to the myelinating glial cells without ensuring by multiple mechanisms. The complete recovery of nodes along the axonal tracts is ensured by multiple mechanisms. The complete recovery of nodes along the axonal tracts is ensured by multiple mechanisms.

Figure 8 | Transient Schwann cell ablation causes permanent disruption of the heminodes and dysmyelination at the HP. (a–f) Heminodes at the habenula perforata (HP) remain disorganized in DTA(+/-):Plp1/Cre(+/-) cochlea (b, d, f) compared control cochlea (a, c, e) at 1 week (a, c). 4 weeks (b, d) and 16 weeks (e, f) after tamoxifen induction. (g) Increased number of aberrant nodal staining (co-localized Caspr/Gliomedin) is observed in DTA(+/-):Plp1/Cre(+/-) cochlea outside the pre-defined 20 µm heminode zone as shown in a–f (below dashed lines, n = 6–10 of each animal group). ***P < 0.001 by two-way ANOVA followed by Bonferroni’s post test. Data are expressed as mean ± s.d. (h, i) Immunostaining for NFH, which preferentially stains unmyelinated axons, indicates the presence of dysmyelinated ANFs as they reach the HP (i, arrow heads) 16 weeks after tamoxifen induction in DTA(+/-):Plp1/Cre(+/-) cochlea. This staining is absent in control mice (h). HP, habenula perforata; IHC, inner hair cells; OSL, osseous spiral lamina. IHCs are stained for Myo7a. (j, k) Representative electron micrographs show dysmyelinated nerve fibres beneath the HP in DTA(+/-):Plp1/Cre(+/-) cochlea (k) but not in control cochlea (j).
Figure 9 | Synaptopathic noise exposure causes further hidden hearing loss in mice that had transient Schwann cell ablation.  

(a) Flow chart showing the experimental design. (b–d) Tamoxifen treatment induces hidden hearing loss characterized by normal ABR thresholds (b), lower ABR P1 amplitudes (c) and longer P1 latencies (d) in DTA(+/–):Plp1/Cre(+/–) mice. (e–g) Hidden hearing loss caused by transient Schwann cell loss persists after noise exposure (8–16 kHz, 98 dB SPL for 2 h). Noise exposure induces further hidden hearing loss in mice with established pathology after Schwann cells loss (h–j) and the control mice (k–m). (n–p) The magnitude of the noise-induced change in DTA(+/-):Plp1/Cre(+/-) mice is the same as that on DTA(+/–) mice. For n–p, physiological data after noise exposure were normalized to that before noise exposure within each genotype. ABR P1 amplitudes and latencies were analysed at 70 dB SPL. n = 8–10 of each group. *P<0.05, **P<0.01 and ***P<0.001 by two-way ANOVA. Data are expressed as mean ± s.e.m.
midline close to the neural crest, (b) behind the left pinna and (c) at the base of the tail (for a ground electrode). ABR potentials were evoked with 5 ms tone pips at 40 s−1. In one case, a 40 s−1 deltam demand was used with a cos2 envelope, at 40 s−1 deltam and 0.5 ms rise–fall, with a cos2 envelope, at 40 s−1 deltam and 0.5 ms rise–fall, with a cos2 envelope. The response was amplified (10,000 × 1) and filtered (0.3–3 kHz) with an analog-to-digital board in a PC-based data-acquisition system. Sound level was raised in 5 dB steps from 10 to 80 dB SPL. At each level, 1,024 responses were averaged (with stimulus polarity alternated) and each of the 256 channels in the response to 40 ms white noise at a frequency of frequency f1 and f2 were recorded at (2 × f1) × f2, with f2/f1 = 1.2, and the f2 level 10 dB lower than the f1 level. Ear-canal sound pressure was amplified and digitally sampled at 4 μs intervals. DPOAE thresholds were defined as the f1 level required to produce a response at −10 dB SPL. Both ABR and DPOAE tonal recordings were performed using EPL cochlear function test suite (Mass Eye and Ear, Boston, MA, USA). ABR peak amplitudes, latencies and widths were analysed with excel and ABR peak analysis software (Mass Eye and Ear).

Noise exposure. Awake wild-type FVB/N mice or DTA(+/−)Plp1/Cre(+/−) and their control mice were placed within small cells in a subdivided cage, suspended in a reverberant noise exposure chamber. FVB/N mice (16 weeks) were exposed to an octave band of noise (8–16 kHz) at 100 dB SPL for 2 h. DTA(+/−)Plp1/Cre(+/−) and control mice (8 weeks) were exposed to the same noise at 98 dB SPL for 2 h. Calibration of noise was performed immediately before each noise exposure to ensure that SPL levels varied by <1 dB across the cages.

Immunohistochemistry and confocal microscopy. Inner ear tissues were dissected and fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 30 min–2 h at room temperature, followed by decalcification in 5% EDTA at 4°C for 5 days. Cochlear tissues were microdissected and permeabilized by freeze–thawing in 30% sucrose. The microdissected tissues were incubated in blocking buffer containing 5% normal horse serum and 0.3% Triton X-100 in PBS for 1 h. Tissues were then incubated in primary antibodies (diluted in blocking buffer) at 37°C for 16 h. The primary antibodies used in this study were as follows: anti-myosin VIIA (rabbit anti-Myo7a; Proteus Biosciences, Ramona, CA; 1:500), anti-Sox2 (goat anti-Sox2; sc-17320, Santa Cruz Biotechnologies, Santa Cruz, CA; 1:200)55, anti-Sox10 (goat anti-Sox10; sc-17342, Santa Cruz Biotechnologies; 1:200)66, anti-MBP (rat anti-MBP; MAB386, EMD Millipore, Billerica, MA; 1:1,000)67, anti-carboxy-terminal binding protein 2 (mouse anti-Ctbp2 IgG1; BD Biosciences, San Jose, CA; 1:200)55, anti-glutamate receptor 2 (mouse anti-GluA2 IgG2a; Millipore, Billerica, MA; 1:2,000)55, anti-NFH (chicken anti-NFH; AB5539, EMD Millipore; 1:2,000)55, anti-Plp1 (gift of Wendy Macklin: 1:500)16, anti-Casp8 (gift of Roman Giger; 1:100)68, anti-gliomedin (gift of Elio Peles; 1:500)59, anti-pan sodium channel (anti-Nav; gift of Roman Giger; 1:75)68, anti-β-fodrin and anti-Angkyn G (gifts of Paul Jenkins; 1:500)59. Tissues were then incubated with appropriate Alexa Fluor conjugated fluorescent secondary antibodies (Invitrogen, Carlsbad, CA; 1:200)55. Images for quantitative analyses of the nodal structures were acquired with a Zeiss LSM710 or a Leica SP8 microscope equipped with a 63 lens with 1.2, and the f2 level 10 dB lower than the f1 level. Ear-canal sound pressure was amplified and digitally sampled at 4 μs intervals. DPOAE thresholds were defined as the f1 level required to produce a response at −10 dB SPL. Both ABR and DPOAE tonal recordings were performed using EPL cochlear function test suite (Mass Eye and Ear, Boston, MA, USA). ABR peak amplitudes, latencies and widths were analysed with excel and ABR peak analysis software (Mass Eye and Ear).

Methods
Animals. Plp1/CreERT2 (Plp1/Crt; stock number 009575), Ai14:Rosa26Tomato (idTomato; stock number 007908) and Rosa26DTA (DTA; stock number 066331) transgenic mice of both genders were obtained from The Jackson Laboratory. Plp1/CreERT2 mice were obtained from Wendy Macklin at the University of Colorado, Denver. To express DTA in cochlear myelinating glial cells, we crossed Plp1/CreERT2 with DTA(+/−)Plp1/CreERT2 mice. Cre-negative littermates were used as controls. For lineage-tracing experiments, Plp1/CreERT2(−/−)idTomato(+/-) or Plp1/CreERT2(−/−)Plp1/eGFP (+/-) mice were crossed with DTA(+/−) mice. Offsprings carrying all three alleles were used for experiments and DTA-negative littermates were used as controls. All mice used in this work were on a mixed background containing C57Bl6 and FVB/N strains, and mice tested for auditory physiology were heterozygous forahl allele. Both males and females were used in this study. The genotypes of the control and experimental animals were blinded to the investigators until the completion of data acquisition and analysis. All animal procedures were approved by the Institutional Animal Care and Use Committee of University of Michigan.

Tamoxifen and EdU injections. Tamoxifen (Sigma, T5648) was dissolved in corn oil (Sigma, C8267) at 37°C to obtain 10 mg ml−1. Mice were injected i.p. with tamoxifen at 50 mg kg−1 per day from P21 to P23. Animals were analysed at 1 week to 1 year after the last tamoxifen injection. To examine cell proliferation, P29 mice were i.p. injected with EdU (obtained from the Click-iT EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific, C10337)) once at 10 mg kg−1 dosage. Mice were killed and tissue analysed at P30. EdU staining was performed following the manufacturer’s instructions.

ABR and DPOAE analyses. ABRs and DPOAEs were performed on mice anaesthetized with xylazine (20 mg kg−1, i.p.) and ketamine (100 mg kg−1, i.p.). For ABR recordings, needle electrodes were placed into the skin (a) at the dorsal
excluded from analysis. All images of semi-thin sections and electron microscope sections shown are representative of at least three individual mice each group.

**Statistical analysis.** Statistical tests were performed using Graphpad Prism 6 (Graphpad Software Inc., La Jolla, CA). Distribution of the data was assumed to be normal, but this was not formally tested. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in our previous publications.15,16,70. Statistical differences in auditory physiology, ribbon synapse counts, densities of myelinated axons, densities of nodes and aberrant nodes were analysed using two-way ANOVA, followed by Bonferromi’s multiple comparisons test. Densities of SGN cell bodies and percentages of SGN cell bodies wrapped by satellite cells were compared using unpaired Student’s t-test. 2-test and frequency distribution plots were used to compare the distribution of axon diameters and g-ratios (axon diameter/axon + myelin sheath diameter) (300–500 axons from 3 mice per group). Student’s t-test was also used to compare the average axon diameter and g-ratio of each mouse.

**Data availability.** All relevant data are included in the manuscript or its Supplementary Information and available from the authors upon request.

**References**

1. Ohlsson, B. O., Neumann, K. J. & Saunders, J. E. The global burden of disabling hearing impairment: a call to action. *Bull. World Health Org.* 92, 367–373 (2014).

2. Baiduc, R. R., Poling, G. L., Hong, O. & Dhar, S. Clinical measures of auditory function: the cochlea and beyond. *Dis. Mon.* 59, 147–156 (2013).

3. Schaeffer, B. R. & McAlpine, D. Timitus with a normal audiogram: physiological evidence for hidden hearing loss and computational model. *J. Neurosci.* 31, 13452–13457 (2011).

4. Liberman, L. D., Suzuki, J. & Liberman, M. C. Dynamics of cochlear synaptopathy after acoustic overexposure. *J. Assoc. Res. Otolaryngol.* 16, 205–219 (2015).

5. Sergeyenko, Y., Lall, K., Liberman, M. C. & Kujawa, S. G. Age-related cochlear synaptopathy: an early-onset contributor to auditory functional decline. *J. Neurosci.* 33, 13668–13694 (2013).

6. Kujawa, S. G. & Liberman, M. C. Adding insult to injury: cochlear nerve degeneration after ‘temporary’ noise-induced hearing loss. *J. Neurosci.* 29, 14077–14085 (2009).

7. Bharadwaj, H. M., Verhulst, S., Shaheen, L., Liberman, M. C. & Shinn-Cunningham, B. G. Cochlear neuropathy and the coding of supra-threshold sound. *Front. Syst. Neurosci.* 8, 26 (2014).

8. Mehraei, G. et al. Auditory brainstem response latency in noise as a marker of cochlear synaptopathy. *J. Neurosci.* 36, 3755–3764 (2016).

9. Liberman, M. C., Epstein, M. J., Cleveland, S. S., Wang, H. & Maison, S. F. Temporal and differential diagnosis of hidden hearing loss in humans. *PLoS ONE* 11, e0162726 (2016).

10. Wan, G. & Corfas, G. No longer falling on deaf ears: mechanisms of degeneration and regeneration of cochlear ribbon synapses. *Hear. Res.* 329, 1–10 (2015).

11. Kujawa, S. G. & Liberman, M. C. Synaptopathy in the noise-exposed and aging ear: a silent majority. *Semin. Cell Dev. Biol.* 71, 258–269 (2016).

12. Kujawa, S. G. & Liberman, M. C. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. *Nat. Rev. Neurosci.* 11, 711–724 (2015).

13. Heinbecher, S. et al. The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. *J. Cell Biol.* 139, 1495–1506 (1997).

14. Hossain, W. A., Antic, S. D., Yang, Y., Rasband, M. N. & Morest, D. K. Where is the spike generator of the cochlear nerve? Voltage-gated sodium channels in the mouse cochlea. *J. Neurosci.* 25, 6857–6868 (2005).

15. Kim, K. X. & Rutherford, M. A. Maturation of NaV and KV channel topographies in the auditory nerve spike initiator before and after developmental onset of hearing function. *J. Neurosci.* 36, 2111–2116 (2016).

16. Eshed, Y. et al. Glomедин mediates Schwann cell-axon interaction and the molecular assembly of the nodes of Ranvier. *Neuron* 47, 215–229 (2005).

17. Lin, H. W., Furman, A. C., Kujawa, S. G. & Liberman, M. C. Primary neural degeneration in the Guinea pig cochlea after reversible noise-induced threshold shift. *J. Assoc. Res. Otolaryngol.* 12, 605–616 (2011).

18. Maw, A. R. Further morphological modifications of the concept of efferent cochlear innervation at an ultrastructural level. *J. Laryngol. Otol.* 87, 619–638 (1973).

19. Suzuki, J., Corfas, G. & Liberman, M. C. Round-window delivery of neurotrophin 3 regenerates cochlear synapses after acoustic overexposure. *Sci. Rep.* 6, 24907 (2016).

20. Shi, L. et al. Noise-induced damage to ribbon synapses without permanent threshold shifts in neonatal mice. *Neuroscience* 304, 368–377 (2015).

21. Siddiqui, A. H. Regulation of conduction time along axons. *Neuroscience* 276, 126–134 (2014).

22. Salzer, J. L. Schwann cell myelination. *Cold Spring Harb. Perspect. Biol.* 7, a020529 (2015).

23. Berger, P., Niemann, A. & Suter, U. Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). *Glia* 54, 243–257 (2006).

24. Griffin, J. W. & Sheikh, K. Schwann cell-axon interactions in Charcot-Marie-Tooth disease. *Ann. N. Y. Acad. Sci.* 883, 77–90 (1999).

25. Dalakas, M. C. Pathophysiology of autoimmune polyneuropathies. *Press. Med.* 42, e181–e192 (2013).

26. Mizutani, S. F., Usukubi, H. & Liberman, M. C. Efferent feedback minimizes cochlear neuropathy from moderate noise exposure. *J. Neurosci.* 33, 5542–5552 (2013).

27. Hashimoto, I. Auditory evoked potentials recorded directly from the human VIIIth nerve and brain stem: origins of their fast and slow components. *Electroencephal. Clin. Neurophysiol. Suppl.* 36, 305–314 (1982).

28. Rajput, A. P. & Darney, S. M. Peak I of the human auditory brainstem response results from the somatic regions of type I spiral ganglion cells evidence from computer modeling. *Hear. Res.* 315, 67–79 (2014).

29. Rutherford, M. A., Chapoknichov, N. M. & Moser, T. Spike encoding of neurotransmitter release timing by spiral ganglion neurons of the cochlea. *J. Neurosci.* 32, 4773–4789 (2012).

30. Burian, B. N. et al. Onset of neurodegeneration is delayed in auditory nerve fibers from mutant mice lacking synaptic ricipons. *J. Neurosci.* 30, 7587–7597 (2010).

31. Eybalin, M., Norenberg, M. D. & Renard, N. Glutamate synthetase and glutamate metabolism in the guinea pig cochlea. *Hear. Res.* 101, 93–101 (1996).

32. Suarez, I., Bodega, G. & Fernandez, B. Glutamine synthetase in brain: effect of glutamate metabolism in the guinea pig cochlea. *Hear. Res.* 36, 215–254 (1988).

33. Suzuki, J., Corfas, G. & Liberman, M. C. Efferent feedback minimizes cochlear neuropathy from moderate noise exposure. *J. Neurosci.* 33, 5542–5552 (2013).

34. Eybalin, M., Norenberg, M. D. & Renard, N. Glutamate synthetase and glutamate metabolism in the guinea pig cochlea. *Hear. Res.* 101, 93–101 (1996).

35. Suarez, I., Bodega, G. & Fernandez, B. Glutamine synthetase in brain: effect of glutamate metabolism in the guinea pig cochlea. *Hear. Res.* 36, 215–254 (1988).

36. Telliez, J., Monnier, J. F., Danner, S. M. Peak I of the human auditory brainstem response results from the somatic regions of type I spiral ganglion cells evidence from computer modeling. *Hear. Res.* 315, 67–79 (2014).

37. Rutherford, M. A., Chapoknichov, N. M. & Moser, T. Spike encoding of neurotransmitter release timing by spiral ganglion neurons of the cochlea. *J. Neurosci.* 32, 4773–4789 (2012).

38. Burian, B. N. et al. Onset of neurodegeneration is delayed in auditory nerve fibers from mutant mice lacking synaptic ricipons. *J. Neurosci.* 30, 7587–7597 (2010).

39. Eybalin, M., Norenberg, M. D. & Renard, N. Glutamine synthetase and glutamate metabolism in the guinea pig cochlea. *Hear. Res.* 101, 93–101 (1996).

40. Suarez, I., Bodega, G. & Fernandez, B. Glutamine synthetase in brain: effect of glutamate metabolism in the guinea pig cochlea. *Hear. Res.* 36, 215–254 (1988).
53. Cashman, C. R. & Hoke, A. Mechanisms of distal axonal degeneration in peripheral neuropathies. *Neurosci. Lett.* **596**, 33–50 (2015).

54. Stoll, C. & Muller, H. W. Nerve injury, axonal degeneration and neural regeneration: basic insights. *Brain Pathol.* **9**, 313–325 (1999).

55. Fricker, F. R. et al. Axonally derived neuregulin-1 is required for remyelination and regeneration after nerve injury in adulthood. *J. Neurosci.* **31**, 3225–3233 (2011).

56. Oluich, L. J. et al. Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination. *J. Neurosci.* **32**, 8317–8330 (2012).

57. Powers, B. E. et al. Remyelination reporter reveals prolonged refinement of spontaneously regenerated myelin. *Proc. Natl Acad. Sci. USA* **110**, 4075–4080 (2013).

58. Sancho, S., Magyar, J. P., Aguzzi, A. & Suter, U. Distal axonopathy in peripheral nerves of Pmp22-mutant mice. *Brain* **122**, 1563–1577 (1999).

59. Elder, G. A. et al. Requirement of heavy neurofilament subunit in the development of axons with large calibers. *J. Cell Biol.* **143**, 195–205 (1998).

60. Kovach, M. J. et al. A unique point mutation in the Pmp22 gene is associated with Charcot-Marie-Tooth disease and deafness. *Am. J. Hum. Genet.* **64**, 1580–1593 (1999).

61. Kabirzada, D. et al. Late-onset Charcot-Marie-Tooth type 2 disease with hearing impairment associated with a novel Pro105Thr mutation in the MPZ gene. *Am. J. Med. Genet.* **143A**, 2196–2199 (2007).

62. Takazawa, T. et al. Sudden deafness and facial palsy in Guillain-Barre Syndrome: radiological depiction of facial and acoustic nerve lesions. *Int. Med.* **51**, 2433–2437 (2012).

63. Nelson, K. R., Gilmore, R. L. & Massey, A. Acoustic nerve conduction abnormalities in Guillain-Barre syndrome. *Neurology* **38**, 1263–1266 (1988).

64. Schiff, J. A., Cracco, R. Q. & Cracco, J. B. Brainstem auditory evoked potentials in Guillain-Barré syndrome. *Neurology* **35**, 771–773 (1985).

65. Cao-Lormeau, V. M. et al. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. *Lancet* **387**, 1531–1539 (2016).

66. Munoz, L. S., Barreras, P. & Pardo, C. A. Zika virus-associated neurological disease in the adult: guillain-barre syndrome, encephalitis, and myelitis. *Semin. Reprod. Med.* **34**, 273–279 (2016).

67. Locher, H. et al. Distribution and development of peripheral glial cells in the human fetal cochlea. *PLoS ONE* **9**, e88086 (2014).

68. Winters, J. J. et al. Congenital CNS hypomyelination in the Fig4 null mouse is rescued by neuronal expression of the PI(3,5)P(2) phosphatase Figk. *J. Neurosci.* **31**, 17736–17751 (2011).

69. Tseng, W. C., Jenkins, P. M., Tanaka, M., Mooney, R. & Bennett, V. Giant ankyrin-G stabilizes somatodendritic GABAergic synapses through opposing endocytosis of GABAA receptors. *Proc. Natl Acad. Sci. USA* **112**, 1214–1219 (2015).

70. Gomez-Casati, M. E. et al. Nonneuronal cells regulate synapse formation in the vestibular sensory epithelium via erbB-dependent BDNF expression. *Proc. Natl Acad. Sci. USA* **107**, 17005–17010 (2010).

Acknowledgements

We thank Roman Giger (University of Michigan) for Caspr and NaV antibodies, Paul Jenkins (University of Michigan) for AnkG and β-spectrin antibodies, Elior Peles (Weizmann Institute of Science) for gliomedin antibodies, Angelica Gigliello for technical assistance and staff at the University of Michigan Microscopy & Image Analysis Laboratory core for help in electron microscopy. We thank M. Charles Liberman, Jochen Schacht, Susan Shore, James Teener and Roman Giger for critical reading of the manuscript. This study is supported by NIH/NIDCD R01DC004820 (to G.C.) and Hearing Health Foundation (to G.W.).

Author contributions

G.W. and G.C. designed the study. G.W. performed the experiments and analysed the data. G.W. and G.C. interpreted the data and wrote the manuscript.

Additional information

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: G.C. is a scientific founder of Decibel Therapeutics, has an equity interest in and has received compensation for consulting. The company was not involved in this study. G.W. declares no competing financial interest

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Wan, G. & Corfas, G. Transient auditory nerve demyelination as a new mechanism for hidden hearing loss. *Nat. Commun.* **8**, 14487 doi: 10.1038/ncomms14487 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/